Palvella Therapeutics Receivables 2014-2024 | PVLA

Palvella Therapeutics receivables from 2014 to 2024. Receivables can be defined as the total amount of collectibles for a company

Palvella Therapeutics Receivables 2014-2024 | PVLA

Palvella Therapeutics receivables from 2014 to 2024. Receivables can be defined as the total amount of collectibles for a company
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$139.4B
Gilead Sciences (GILD)$114.7B
Bristol Myers Squibb (BMY)$113.7B
Vertex Pharmaceuticals (VRTX)$102.8B
CSL (CSLLY)$85.4B
Regeneron Pharmaceuticals (REGN)$77.2B
GSK (GSK)$69.7B
Argenex SE (ARGX)$37.4B
Alnylam Pharmaceuticals (ALNY)$30.4B
BioNTech SE (BNTX)$27B
Biogen (BIIB)$21.9B
Illumina (ILMN)$21.2B
BeiGene (BGNE)$17.9B
Moderna (MRNA)$15.2B
Genmab (GMAB)$13.7B
Incyte (INCY)$13.2B
BioMarin Pharmaceutical (BMRN)$12.5B
Insmed (INSM)$12.3B
Sarepta Therapeutics (SRPT)$11.6B
Bio-Techne Corp (TECH)$11.5B
Exact Sciences (EXAS)$10.4B
Vaxcyte (PCVX)$10.2B
QIAGEN (QGEN)$10.2B
Swedish Orphan Biovitrum (BIOVF)$9.8B
Exelixis (EXEL)$9.6B
Bio-Rad Laboratories (BIO.B)$9.1B
Intra-Cellular Therapies (ITCI)$8.9B
Roivant Sciences (ROIV)$8.3B
Ascendis Pharma (ASND)$8.3B
Repligen (RGEN)$8.1B